Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
BIA Monitoring and Exercise for the Prevention of Muscle Loss With Incretin Therapy (BICEP Study)
Who can join
Ages 18 to 99 · All sexes
Full eligibility criteria
Inclusion Criteria 1. Age ≥ 18 years old at time of signing informed consent 2. Started treatment with incretin therapy (liraglutide, semaglutide, tirzepatide, or retatrutide) within the past 2 months or planning to start this treatment a. Potential participants switching GLP1-RA therapies due to inadequate response to a prior treatment will be eligible for enrollment 3. Able to provide informed consent Exclusion Criteria 1. Current pregnancy (positive urine hCG) or plans to become pregnant in the next 6 months 2. BMI \<25 kg/m2 at the time of screening 3. Unable to participate in a regular physical exercise program 4. Implanted pacemaker 5. Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study
About the study
The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.
What is being tested
- Smartwatch activity and body composition monitor (device)
- General guidance on recommended exercise (behavioral)
Sponsor: Massachusetts General Hospital · Participants: 100 · Started: Nov 24, 2025
Contact the study team
- Ben O Brenner, BS · Phone: 617-726-1729
Official record on ClinicalTrials.gov — NCT07226947
Locations in the U.S.
| Massachusetts | Diabetes Research Center, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.